Arteritis Clinical Trial
Official title:
Randomised Study Comparing Endothelialised Prosthesis and Autologous Vein for Under Knee Revascularisation With Femoro Popliteal Bypass. ePTFE
The aim of this project is to improve the hemocompatibility of vascular prosthesis with a complete covering of its endoluminal surface with autologous endothelial cells. The objective is to obtain a better bypass permeability with arterial prosthesis replacing low diameter vessels in lower limbs
Physiological vascular endothelium is an hemocompatible and thrombus resistant surface and
none of the materials used for revascularisation owns these properties. The aim of this
project is to improve the hemocompatibility of vascular prosthesis with a complete covering
of their endoluminal surface with autologous endothelial cells. This strategy, that plans to
associate an artificial component of synthetic origin and cellular component is a
bioartificial vascular substitute concept. First results obtained by an austrian team are
really encouraging (with more than 100 patients during last 10 years). Thus, the main
objective of this study is to compare efficacy in terms of grafts with endothelialised PTFE
prosthesis with great saphenous autologous vein graft for under knee arterial popliteal
revascularisation of lower limbs.
This is a phase III, randomised equivalent trial. It is open labelled, with 2 parallel well
balanced groups. Forty patients will be randomised. A short segment of the cephalic vein
will be cut and some blood will be sampled in patients randomised in the ePTFE group.
Endothelial cells of the cephalic vein will be isolated, cultured, with autologous serum,
and then amplified before sowing of the internal face of PTFE prosthesis, previously covered
with a biological glue clinically validated. Before prosthesis implantation, systematic
quality controls will be performed. Implantation will be planned 3 weeks after venous
sampling. Eventual failure of cellular culture or prosthesis covering will lead to an
autologous vein graft. People randomised in the second group will receive an autologous
saphenous vein graft.
The primary outcome is to demonstrate the equivalence of time dependent permeability rate
between endothelialized PTFE and autologous vein graft. Equivalence between both technics
would allow to preserve autologous saphenous vein for later distal bypasses (where it is the
best technic) or for coronary bypasses.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02089828 -
Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia
|
N/A | |
Recruiting |
NCT05437965 -
Biomarkers of Isolated Coronary Arteritis and Related Pathogenic Mechanism
|
||
Recruiting |
NCT03543527 -
Study of Refractory and/or Relapsing TAkayasu aRTeritis
|
||
Completed |
NCT00221715 -
Comparison of Two Lower Limb Bypass Types : Prosthesis Versus Autologous Vein
|
N/A | |
Completed |
NCT01795456 -
Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis
|
N/A | |
Not yet recruiting |
NCT01323504 -
Pain and Music Therapy in Patients Suffering Arteritis
|
Phase 3 |